Enhanced Expression of CD13 in Vessels of Inflammatory and Neoplastic Tissues

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma

(2010) A Santoro et al.   BRITISH JOURNAL OF CANCER

Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041)

(2010) H. W.M. van Laarhoven et al.   CLINICAL CANCER RESEARCH

Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy

(2010) Armando Santoro et al.   EUROPEAN JOURNAL OF CANCER

Phase II Study of Asparagine-Glycine-Arginine–Human Tumor Necrosis Factor α, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma

(2010) Vanesa Gregorc et al.   JOURNAL OF CLINICAL ONCOLOGY

The 140-kDa Protein of Blood-Brain Barrier-Associated Pericytes Is Identical to Aminopeptidase N

(2010) Jörg Kunz et al.   JOURNAL OF NEUROCHEMISTRY

Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

(2009) V Gregorc et al.   BRITISH JOURNAL OF CANCER

Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours

(2009) Vanesa Gregorc et al.   EUROPEAN JOURNAL OF CANCER

Aminopeptidase N (APN)/CD13 inhibitor, Ubenimex, enhances radiation sensitivity in human cervical cancer

(2008) Hirohisa Tsukamoto et al.   BMC CANCER

The moonlighting enzyme CD13: old and new functions to target

(2008) Paola Mina-Osorio   TRENDS IN MOLECULAR MEDICINE

Aminopeptidase N (APN)/CD13-dependent CXCR4 downregulation is associated with diminished cell migration, proliferation and invasion

(2007) Jens Wulfaenger et al.   MOLECULAR MEMBRANE BIOLOGY